178 related articles for article (PubMed ID: 30591493)
1. PD-1 Expression on Circulating CD8
Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Miyatani K; Matsunaga T; Fukumoto Y; Ashida K; Fujiwara Y
Anticancer Res; 2019 Jan; 39(1):443-448. PubMed ID: 30591493
[TBL] [Abstract][Full Text] [Related]
2. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer.
Saito H; Kuroda H; Matsunaga T; Osaki T; Ikeguchi M
J Surg Oncol; 2013 Apr; 107(5):517-22. PubMed ID: 23129549
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis.
Bartosińska J; Zakrzewska E; Król A; Raczkiewicz D; Purkot J; Majdan M; Krasowska D; Chodorowska G; Giannopoulos K
Pol Arch Intern Med; 2017 Dec; 127(12):815-822. PubMed ID: 29112182
[TBL] [Abstract][Full Text] [Related]
4. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
Takano S; Saito H; Ikeguchi M
Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
[TBL] [Abstract][Full Text] [Related]
5. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
Anticancer Res; 2018 Jan; 38(1):107-112. PubMed ID: 29277762
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103
Li R; Liu H; Cao Y; Wang J; Chen Y; Qi Y; Lv K; Liu X; Yu K; Lin C; Zhang H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
Br J Cancer; 2020 May; 122(10):1525-1534. PubMed ID: 32205862
[TBL] [Abstract][Full Text] [Related]
7. Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer.
Rozsypalova A; Rosova B; Filipova A; Nikolov DH; Chloupkova R; Richter I; Proks J; Zachoval R; Matej R; Melichar B; Buchler T; Dvorak J
J BUON; 2019; 24(4):1644-1651. PubMed ID: 31646820
[TBL] [Abstract][Full Text] [Related]
8. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis.
Ruan Y; Wang J; Zhang Q; Wang H; Li C; Xu X; Zhai Z
Eur J Med Res; 2023 Sep; 28(1):383. PubMed ID: 37759316
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia.
Rusak M; Eljaszewicz A; Bołkun Ł; Łuksza E; Łapuć I; Piszcz J; Singh P; Dąbrowska M; Bodzenta-Łukaszyk A; Kłoczko J; Moniuszko M
Pol Arch Med Wewn; 2015; 125(7-8):553-9. PubMed ID: 26140546
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
[TBL] [Abstract][Full Text] [Related]
14. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
[TBL] [Abstract][Full Text] [Related]
15. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer.
Osaki T; Saito H; Yoshikawa T; Matsumoto S; Tatebe S; Tsujitani S; Ikeguchi M
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):382-7. PubMed ID: 17255258
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Akagi J; Baba H
Oncol Rep; 2019 Jan; 41(1):301-311. PubMed ID: 30542740
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression and CD8
Wang Y; Zhu C; Song W; Li J; Zhao G; Cao H
J Immunol Res; 2018; 2018():4180517. PubMed ID: 30003113
[TBL] [Abstract][Full Text] [Related]
18. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
[TBL] [Abstract][Full Text] [Related]
19. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
Ohmura H; Yamaguchi K; Hanamura F; Ito M; Makiyama A; Uchino K; Shimokawa H; Tamura S; Esaki T; Mitsugi K; Shibata Y; Oda H; Tsuchihashi K; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
Br J Cancer; 2020 May; 122(10):1507-1517. PubMed ID: 32203221
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
